Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ombretta Viapiana

Showing results (1-10 of 252) with videos related to

Pageof 26
Sort By:
The Journal of Dermatological Treatment|November 8, 2018
Treatment with secukinumab in multi-comorbid patients with psoriatic arthritisOmbretta Viapiana, Elena Fracassi
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 2, 2026
Response to: Letter to the editor regarding: Real‑world rebound pattern of serum collagen type I C‑telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment‑induced bone lossFederico Aldegheri, Maurizio Rossini, Ombretta Viapiana
Clinical Therapeutics|August 22, 2009
Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated reviewMaurizio Rossini, Ombretta Viapiana, Davide Gatti, et al.
Clinical Drug Investigation|January 13, 2022
Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17Ombretta Viapiana, Soohyun Lee, SangWook Yoon, et al.
Expert Opinion on Pharmacotherapy|September 12, 2015
The use of bisphosphonates in women: when to use and when to stopDavide Gatti, Silvano Adami, Ombretta Viapiana, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 19, 2026
Response to: Letter comments on: Radiofrequency Echographic Multi Spectrometry (REMS) for the evaluation of bone health in systemic lupus erythematosus (SLE)Giovanni Adami, Davide Gatti, Ombretta Viapiana, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 26, 2009
Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressivaDavide Gatti, Ombretta Viapiana, Maurizio Rossini, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 4, 2022
Cardiovascular Safety of Romosozumab: New Insights from Postmenopausal Women with Chronic Kidney DiseaseGiovanni Adami, Davide Gatti, Angelo Fassio, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 2, 2022
Acute Phase Reaction and Fracture Risk Reduction: Are Gamma-Delta T Cells and Hypovitaminosis D the Missing Link?Giovanni Adami, Angelo Fassio, Davide Gatti, et al.
Therapeutics and Clinical Risk Management|April 17, 2013
Clinical development of neridronate: potential for new applicationsDavide Gatti, Maurizio Rossini, Ombretta Viapiana, et al.
Pageof 26

Showing results (1-10 of 252) with videos related to

Sort By:
Pageof 26
The Journal of Dermatological Treatment|November 8, 2018
Treatment with secukinumab in multi-comorbid patients with psoriatic arthritisOmbretta Viapiana, Elena Fracassi
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 2, 2026
Response to: Letter to the editor regarding: Real‑world rebound pattern of serum collagen type I C‑telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment‑induced bone lossFederico Aldegheri, Maurizio Rossini, Ombretta Viapiana
Clinical Therapeutics|August 22, 2009
Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated reviewMaurizio Rossini, Ombretta Viapiana, Davide Gatti, et al.
Clinical Drug Investigation|January 13, 2022
Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17Ombretta Viapiana, Soohyun Lee, SangWook Yoon, et al.
Expert Opinion on Pharmacotherapy|September 12, 2015
The use of bisphosphonates in women: when to use and when to stopDavide Gatti, Silvano Adami, Ombretta Viapiana, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 19, 2026
Response to: Letter comments on: Radiofrequency Echographic Multi Spectrometry (REMS) for the evaluation of bone health in systemic lupus erythematosus (SLE)Giovanni Adami, Davide Gatti, Ombretta Viapiana, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 26, 2009
Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressivaDavide Gatti, Ombretta Viapiana, Maurizio Rossini, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 4, 2022
Cardiovascular Safety of Romosozumab: New Insights from Postmenopausal Women with Chronic Kidney DiseaseGiovanni Adami, Davide Gatti, Angelo Fassio, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 2, 2022
Acute Phase Reaction and Fracture Risk Reduction: Are Gamma-Delta T Cells and Hypovitaminosis D the Missing Link?Giovanni Adami, Angelo Fassio, Davide Gatti, et al.
Therapeutics and Clinical Risk Management|April 17, 2013
Clinical development of neridronate: potential for new applicationsDavide Gatti, Maurizio Rossini, Ombretta Viapiana, et al.
Pageof 26